TRAF2 and NCK-interacting kinase (TNIK) (TNIK)

TRAF2 and NCK-interacting kinase (TNIK), also known as Mitogen-activated protein kinase kinase kinase kinase 7 (MAP4K7), is a serine/threonine kinase belonging to the germinal center kinase (GCK) family [24, 28]. It serves as a critical integrator of multiple signaling pathways, most notably the Wnt/β-catenin and JNK cascades, which are essential for cell proliferation, differentiation, and survival [24, 33]. In the nucleus, TNIK is an essential activator of Wnt target genes through its interaction with and phosphorylation of TCF4, which drives the expression of oncogenic factors such as c-MYC [26, 33]. Beyond its role in transcription, TNIK regulates cytoskeletal organization and cell migration, making it a significant driver of cancer progression, metastasis, and treatment resistance in various malignancies, including colorectal and lung squamous cell carcinoma [30, 33]. In addition to oncology, TNIK has emerged as a key therapeutic target in fibrotic diseases and neurodegeneration [25, 33]. It promotes myofibroblast activation and extracellular matrix deposition, and its inhibition has shown clinical promise in treating idiopathic pulmonary fibrosis (IPF), with the AI-discovered inhibitor rentosertib currently in Phase 2 trials [25, 27]. In the nervous system, TNIK is highly expressed in the brain and is vital for synaptic function and neurite outgrowth; however, its dysregulation is linked to schizophrenia and neurodegenerative conditions like ALS [5, 10, 24]. Pharmacological targeting of TNIK aims to modulate these pathological processes, though potential cognitive side effects remain a consideration due to its fundamental role in neuronal signaling [24, 33].

Other names

Mitogen-activated protein kinase kinase kinase kinase 7MAP4K7TRAF2 and NCK-interacting protein kinaseTNIK

Inhibition of TNIK kinase activity, which disrupts the Wnt/β-catenin signaling pathway by preventing the phosphorylation of TCF4, and modulates the JNK signaling pathway by regulating DLK activation. In fibrotic diseases, it inhibits myofibroblast activation and extracellular matrix production.